Drugs / Tenofovir Amibufenamide
Tenofovir Amibufenamide
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07295873 | Dec 2025 → Jun 2026 overdue | fibrotic liver disease | Beijing Continent Pharmaceutical Co, Ltd. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05382351 | May 2022 → Apr 2024 | chronic hepatitis B virus infection | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06743438 | Mar 2022 → Jun 2024 overdue | chronic hepatitis B virus infection | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05797714 | Jun 2022 → Apr 2024 overdue | chronic hepatitis B virus infection | Ruijin Hospital | Active not recruiting | No outcome recorded |
| — | NCT05398393 | Jan 2022 → Jun 2023 | chronic hepatitis B virus infection, lip disorder | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07553767 Background | Mar 2026 → Dec 2034 expected | chronic hepatitis B virus infection, hepatocellular carcinoma | Ningbo No.2 Hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06323681 Comparator | Feb 2024 → Feb 2027 expected | chronic hepatitis B virus infection | Qing XIe | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tenofovir amibufenamide | “First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally,...” NCT06323681 ↗6“Tenofovir amibufenamide” NCT07553767 ↗ |
| Known as | HS-10234 | “Tenofovir amibufenamide (TMF; codename: HS-10234), another formulation of tenofovir, shared the same ProTide technology as tenofovir alafenamide, which can provide more...” NCT05797714 ↗ |
| Known as | TMF | “First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally,...” NCT06323681 ↗4“Tenofovir amibufenamide (TMF) is a novel prodrug of tenofovir that has been widely used in mainland China for the treatment of chronic hepatitis B (CHB).” NCT06743438 ↗ “new drug Tenofovir Amibufenamide(TMF)” NCT05398393 ↗ “Drug: Tenofovir Amibufenamide（TMF）” NCT05797714 ↗ “Tenofovir Amibufenamide(TMF)” NCT07295873 ↗ |
| Route | Oral | “enofovir amibufenamide orally 25mg once a day with meals” NCT05382351 ↗ |